The U.S. formulations revenue increase was primarily driven by volume gains and new launches, partially offset by no transient product sales; Europe formulations revenue driven by robust performance across all key market.
The U.S. formulations revenue increase was primarily driven by volume gains and new launches, partially offset by no transient product sales; Europe formulations revenue driven by robust performance across all key market.
<iframe src="https://hindustansphere.com/embed/cluster/0d1c5aa62327cfbcd396bb005d78476cc66313c7" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Aurobindo Pharma Q1 net rises 25% to ₹1,032 cr; approves merger of three arms"></iframe>
